Previous 10 | Next 10 |
ALACHUA, Fla., May 20, 2020 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for damage or discontinuity to peripheral nerves, today announced that Karen Zaderej, chairman, CEO, and president will present at the Jef...
The following slide deck was published by AxoGen, Inc. in conjunction with their 2020 Q1 earnings Read more ...
AxoGen, Inc. (AXGN) Q1 2020 Earnings Conference Call May 06, 2020 16:30 A.M. ET Company Participants Karen Zaderej - Chairman, President, and CEO Peter J. Mariani - CFO Conference Call Participants Unidentified Analyst - SVB Leerink Rajbir Denhoy - Jefferies David Turkaly...
Gainers: Tetraphase Pharmaceuticals (NASDAQ: TTPH ) +90% . More news on: Tetraphase Pharmaceuticals, Inc., ION Geophysical Corporation, Twilio Inc., Stocks on the move, , Read more ...
AxoGen (NASDAQ: AXGN ): Q1 Non-GAAP EPS of -$0.19 misses by $0.04 ; GAAP EPS of -$0.21 beats by $0.03 . More news on: AxoGen, Inc., Earnings news and commentary, Stocks on the move, Healthcare stocks news, Read more ...
ALACHUA, Fla., May 06, 2020 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today reported financial results and business highlights for the first quarter ended March 31, 2020. Firs...
ALACHUA, Fla., April 15, 2020 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for damage or transection to peripheral nerves, today announced that it will report first quarter 2020 financial results on Wednesday, May...
Today, we will study why Organogenesis ( ORGO ) is a high growth yet undervalued opportunity in 2020. Company overview Organogenesis is a regenerative medicine company focusing on the development and commercialization of products for treating chronic and acute wounds and healing of muscu...
AxoGen, Inc. (AXGN) Q4 2019 Earnings Conference Call February 24, 2020 04:30 PM ET Company Participants Peter Mariani - Chief Financial Officer Karen Zaderej - Chairman, President and Chief Executive Officer Conference Call Participants Rajbir Denhoy - Jefferies LLC Richard...
The following slide deck was published by AxoGen, Inc. in conjunction with their 2019 Q4 earnings Read more ...
News, Short Squeeze, Breakout and More Instantly...
ALACHUA and TAMPA, Fla., July 23, 2024 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced that it will report second quarter 2024 financial results on Thursday, August 8, 2024, b...
2024-07-01 07:30:05 ET Raymond James analyst issues OUTPERFORM recommendation for AXGN on July 1, 2024 05:51AM ET. AXGN was trading at $7.24 at issue of the analyst recommendation. Historical Analyst Recommendations Latest 10 recommendations
ALACHUA, Fla. and TAMPA, Fla., July 01, 2024 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, announced making an inducement grant on July 1, 2024, under NASDAQ listing rule 5635(c)(4) in conn...